

PEXA signs agreement with global pharmaceutical company for 10 instruments for clinical multicenter study in pulmonary fibrosis, with a value of approximately SEK 7.5 million

PEXA AB has signed an agreement with one of the world's ten largest pharmaceutical companies regarding the delivery, installation and rental of ten PEXA 2.1 systems for use in an international clinical study in idiopathic pulmonary fibrosis (IPF).

Under the agreement, the customer will rent ten systems for a period of 18 months. The total order value during the agreement period amounts to approximately SEK 7.5 million, including consumables, service, support and related services. Half of the amount, totaling just over SEK 3.5 million, is expected to be invoiced during the second quarter of 2026. Thereafter, recurring quarterly rental revenues will follow during the agreement period. Deliveries and installations are planned to commence during the third quarter of 2026.

The study will use PEXA's technology for non-invasive collection of biological material from the small airways of the lung. The collected samples enable biomarker analyses and drug-related analyses directly from the "site of action", meaning the part of the lung affected by the disease and where the treatment is most relevant.

"This is an important milestone for PEXA. The fact that a global pharmaceutical company has chosen to use our technology in a clinical multicenter study is a strong validation of the platform we have built over many years. The agreement also creates an important reference for PEXA and demonstrates that we have the capacity to deliver, install and support larger international research and drug development projects," says Tomas Gustafsson, CEO of PEXA AB.

PEXA's technology enables the collection of biological material via exhaled breath from the distal parts of the lung. The method creates new opportunities in biomarker development, drug development, pharmacokinetic and pharmacodynamic studies (PK/PD), as well as future precision medicine and diagnostic applications.

This information is information that PEXA AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the stated contact person, on 2026-06-23.

This is an English translation of the original Swedish press release. In the event of any discrepancy, the Swedish original shall prevail.

For further information, please contact:

Tomas Gustafsson, CEO, info@pexa.se

About PEXA AB:



PEXA AB PEXA AB (556956-9246) has developed the PEXA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PEXA's technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PEXA's method. The company's long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PEXA addresses a significantly wider market, which today includes several million patients globally.

PEXA's B share is listed on the Spotlight Stock Market.